We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Mereo Biopharma Group Plc | LSE:MPH | London | Ordinary Share | GB00BZ4G2K23 | ORD GBP0.003 (REG S) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 26.50 | 26.00 | 27.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMMPH
RNS Number : 5582L
Mereo BioPharma Group plc
27 December 2018
Mereo BioPharma Group plc
("Mereo" or the "Company")
Notification of PCA Dealing
London, 27 December 2018 - Mereo BioPharma Group plc (AIM: MPH), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification that on 21 December 2018, Eric Scots-Knight, a person closely associated (PCA) with Denise Scots-Knight, Chief Executive Officer of Mereo, purchased ordinary shares of GBP0.003 each in the Company, as set out in the following table.
The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The form required under the EU Market Abuse Regulation follows.
DEALING NOTIFICATION FORM
FOR USE BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY AND THEIR CLOSELY ASSOCIATED PERSONS
1 Details of the person discharging managerial responsibilities / person closely associated a) Name Eric Scots-Knight ------------------------ --------------------------------------------- 2 Reason for the notification ----------------------------------------------------------------------- a) Position/status PCA of Denise Scots-Knight, Chief Executive Officer ------------------------ --------------------------------------------- b) Initial notification Initial Notification / Amendment ------------------------ --------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ----------------------------------------------------------------------- a) Name Mereo BioPharma Group plc ------------------------ --------------------------------------------- b) LEI 213800U8JQHIJOS5AS09 ------------------------ --------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ----------------------------------------------------------------------- a) Description of Ordinary Shares of GBP0.003 each the financial instrument, type ISIN: GB00BZ4G2K23 of instrument Identification code: ------------------------ --------------------------------------------- b) Nature of the Purchase of shares transaction ------------------------ --------------------------------------------- c) Price(s) and 185 pence. 3000 Ordinary Shares of GBP0.003 volume(s) each ------------------------ --------------------------------------------- d) Aggregated information 185 pence. 3000 Ordinary Shares of GBP0.003 each. ------------------------ --------------------------------------------- e) Date of the transaction 21 December 2018 ------------------------ --------------------------------------------- f) Place of the London Stock Exchange transaction ------------------------ ---------------------------------------------
Enquiries:
Mereo BioPharma Group plc +44 (0)333 023 7300 Denise Scots-Knight, Chief Executive Officer Richard Jones, Chief Financial Officer Cantor Fitzgerald Europe (Nominated Adviser and Broker) +44 (0)20 7894 7000 Phil Davies Will Goode Rick Thompson RBC Capital Markets (Joint Broker) +44 (0)20 7653 4000 Rupert Walford Jamil Miah FTI Consulting (Public Relations Adviser) +44 (0)20 3727 1000 Simon Conway Brett Pollard Burns McClellan (US Public Relations Advisor to Mereo Biopharma) +01 (0) 212 213 0006 Lisa Burns Ami Bavishi
About Mereo
Mereo is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare diseases. Mereo's strategy is to selectively acquire product candidates that have already received significant investment from pharmaceutical companies and that have substantial preclinical, clinical and manufacturing data packages. In December 2018, Mereo announced the proposed combination of Mereo and OncoMed Pharmaceuticals, with the transaction expected to close in the first half of 2019. Each of Mereo's four product candidates has previously generated positive clinical data for Mereo's target indication or in a related indication. Since inception Mereo has commenced large, randomized, placebo-controlled Phase 2 clinical trials for all four of the product candidates:
-- BPS-804 for osteogenesis imperfecta (OI). The Company recently announced completion of enrolment with 112 adult patients in a Phase 2b dose ranging study with some initial data expected in the H1 2019 and top-line dose ranging data in late 2019. A pediatric Phase 3 study design has also been approved by the EMA. BPS-804 has orphan designation in the US and EU and has been accepted into the PRIME and Adaptive Pathways in EU;
-- MPH-966 for alpha-1 antitrypsin deficiency (AATD). The Company recently announced first patient in in a Phase 2 dose ranging study in the US with data expected in late 2019;
-- BCT-197 for acute exacerbations of COPD (AECOPD). The Company announced positive top-line Phase 2 data in December 2017; and
-- BGS-649 for hypogonadotropic hypogonadism (HH). The Company announced positive top-line Phase 2b data in March 2018 and positive results in December 2018 from the safety extension to the Phase 2b clinical trial.
-- As at September 30, 2018 Mereo had (unaudited) total cash resources of approximately US$44.6 million
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHKDLBLVLFEFBV
(END) Dow Jones Newswires
December 27, 2018 05:02 ET (10:02 GMT)
1 Year Mereo Biopharma Chart |
1 Month Mereo Biopharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions